UPLOAD Filing
ACADIA PHARMACEUTICALS INC
Date: May 14, 2025 · CIK: 0001070494 · Accession: 0000000000-25-005177
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-287145
Letter
Re: Acadia Pharmaceuticals Inc. Registration Statement on Form S-3 Filed May 9, 2025 File No. 333-287145 Dear Catherine Owen Adams:
May 14, 2025
Catherine Owen Adams Chief Executive Officer Acadia Pharmaceuticals Inc. 12830 El Camino Real, Suite 400 San Diego, CA 92130
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Carlos Ramirez, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> May 14, 2025 Catherine Owen Adams Chief Executive Officer Acadia Pharmaceuticals Inc. 12830 El Camino Real, Suite 400 San Diego, CA 92130 Re: Acadia Pharmaceuticals Inc. Registration Statement on Form S-3 Filed May 9, 2025 File No. 333-287145 Dear Catherine Owen Adams: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Carlos Ramirez, Esq. </TEXT> </DOCUMENT>